



Data presented at VEITH Symposium show 30% increase in one-year success rates for vascular bypass surgery, and dramatic reduction in amputations

Dundee, UK, 18 November, 2014 – Vascular Flow Technologies announce that study results will be presented this weekend at the 41st Annual VEITH Symposium on Vascular and Endovascular Issues in New York, showing a 30% increase in one-year success for infrainguinal vascular bypass surgery in patients who received a Spiral Flow™ Graft compared to those who received a standard polytetrafluoroethylene (PTFE) graft.

The study shows one-year primary and secondary patency rates of 76% and 87% for Spiral Flow™ Grafts (n=54), compared to 48% and 55% for PTFE bridge graft (n=124), as well as a dramatically lower amputation rate in patients receiving Spiral Flow™ Grafts (2% vs 10%).

The study was led by Mr Nick Shaper FRCS, Consultant Vascular Surgeon at Bradford Royal Infirmary, UK. Mr Shaper said: "All patients demonstrated post-operative spiral laminar flow at the distal anastomosis, and there was a substantial and highly encouraging improvement in one year patency rates in this group of patients."

Spiral Laminar Flow™ (SLF™) technology is the only vascular graft technology that is proven to replicate natural blood flow by generating a spiral laminar flow within the graft, reducing turbulence at the point where the blood flows into the blood vessel,^{1,2} which limits changes to the blood vessel wall that may be precursors to thrombosis.³ These findings add to the growing body of evidence demonstrating improved clinical outcomes for patients who receive a Spiral Flow™ Graft.

The VEITH Symposium will also hear from Professor Richard Neville, Chief of the Division of Vascular Surgery, George Washington University Hospital. Professor Neville will present an update on the newly opened US registry for Spiral Flow™ arteriovenous (AV) grafts in haemodialysis access. The Spiral Flow™ AV Access Graft Clinical Registry will collect the primary, primary assisted and secondary patency rates of the Spiral Flow™ AV Access Graft in patients with End Stage Renal Disease (ESRD) as well as recording complication rates.

The registry will provide data to its physician users detailing their patients' graft performance data compared to national performance. The registry will hold demographic, operative and postoperative graft performance data, and results. Findings will be presented at local, regional and national vascular conferences in the months ahead.

Bill Allan, CEO of Vascular Flow Technologies commented: "Clinical experience with Spiral Flow™ Grafts is continuing to grow, and the newly opened US registry will provide a further bank of data for evaluation of long-term patency and complication rates. We are encouraging haemodialysis physicians to view the portal and to seek Institutional Review Board (IRB) approval to start entering patient data."

The Vascular Flow Clinical Registry portal can be accessed at www.vascular-flow-clinical-registry.com.

-Ends-

Notes to Editors

About Vascular Flow Technologies

Vascular Flow Technologies is a leading innovator focused on the research, development and commercialisation of devices to improve blood flow in compromised or diseased blood vessels utilising its proprietary Spiral Laminar Flow™ (SLF™) technology. Natural blood flow has a distinctive singular spiral flow pattern and the patented SLF™ technology is the only clinically-proven design to replicate this.

VFT has two CE marked and FDA approved devices commercialised in Europe and the US, the Spiral Flow™ peripheral bypass (PV) graft and the Spiral Flow™ arteriovenous access (AV) graft. The SLF™ technology is used to create a longer lasting graft or stent, producing a better quality of life for the patient due to reduced vascular complications and improved longevity of the implant.

VFT is a privately held company with headquarters in Dundee, UK.

Further information is available at www.vascular-flow.com.

About the study

The study, *Spiral Flow Prosthetic Grafts in Lower Extremity Bypasses – one year and beyond*, compared prospective data on primary and secondary patency rates, interventions and complications at one year post-operation in 54 patients undergoing infrainguinal bypass using SLF grafts between 2011 and 2014, with retrospective data on all infrainguinal grafts (n=124) conducted using a conventional bridge graft between 2003 and 2008.

The abstract will be available after the meeting at:

<http://www.veithsymposium.org/index.php?pg=program-2014>

About VEITHsymposium

Now in its fourth decade, VEITHsymposium provides vascular surgeons, interventional radiologists, interventional cardiologists and other vascular specialists with a unique and exciting format to learn the most current information about what is new and important in the treatment of vascular disease.

The 5-day event features over 750 rapid-fire presentations from world-renowned vascular specialists with emphasis on the latest advances, changing concepts in diagnosis and management, pressing controversies and new techniques. To register to attend the VEITHsymposium, please visit www.VEITHpress.org or contact Pauline T. Mayer at 631.979.3780.

For more information, please contact:

Bill Allan

CEO, Vascular Flow Technologies

Telephone: +44 (0) 1382 598 532

Email: info@vascular-flow.com

For media enquiries, please contact:

Dr Lynne Trowbridge / Ruth Ashton

Instinctif Partners

Telephone: +44 207 866 7936

Email: VFT@instinctif.com

References:

1. Stonebridge PA, Buckley C, Thompson A, Dick J, Hunter G, Chudek JA, Houston JG, Belch JJ. Non spiral and spiral (helical) flow patterns in stenosis. In vitro observations using spin and gradient echo magnetic resonance imaging (MRI) and computational fluid dynamic modelling. In *Angiol* 2004 Sep;23(3):276-83.
2. Kokkalis E, Hoskins P, Corner G, Stonebridge P, Doull A, Houston G. Secondary flow in peripheral vascular prosthetic grafts using vector Doppler imaging. *Ultrasound in Med & Biol* 2013;39(12):2295-2307.
3. El Sayed HF. Vascular Flow Technology: Another run of the mill graft or a breakthrough technology? US experience and perspective. Presented at the 8th International St George's Vascular Access Meeting at the 35th Charing Cross international vascular and endovascular symposium, 7th April 2013, London.

MK034/01